ciglitazone has been researched along with Melanoma in 7 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have previously demonstrated that the thiazolidinedione ciglitazone inhibited, independently of PPARγ activation, melanoma cell growth." | 7.77 | Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth. ( Ballotti, R; Bertolotto, C; Botton, T; Cheli, Y; Deckert, M; Fajas, L; Giuliano, S; Ortonne, JP; Puissant, A; Rocchi, S; Tartare-Deckert, S; Tomic, T, 2011) |
| " In this report, focusing our attention on ciglitazone, we show that ciglitazone inhibits melanoma growth by inducing apoptosis and cell-cycle arrest, whereas normal melanocytes are resistant to ciglitazone." | 7.75 | In vitro and in vivo anti-melanoma effects of ciglitazone. ( Annicotte, JS; Bahadoran, P; Ballotti, R; Bertolotto, C; Botton, T; Fajas, L; Gozzerino, G; Ortonne, JP; Puissant, A; Rocchi, S; Tartare-Deckert, S; Zamoum, T, 2009) |
| "We have previously demonstrated that the thiazolidinedione ciglitazone inhibited, independently of PPARγ activation, melanoma cell growth." | 3.77 | Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth. ( Ballotti, R; Bertolotto, C; Botton, T; Cheli, Y; Deckert, M; Fajas, L; Giuliano, S; Ortonne, JP; Puissant, A; Rocchi, S; Tartare-Deckert, S; Tomic, T, 2011) |
| " In this report, focusing our attention on ciglitazone, we show that ciglitazone inhibits melanoma growth by inducing apoptosis and cell-cycle arrest, whereas normal melanocytes are resistant to ciglitazone." | 3.75 | In vitro and in vivo anti-melanoma effects of ciglitazone. ( Annicotte, JS; Bahadoran, P; Ballotti, R; Bertolotto, C; Botton, T; Fajas, L; Gozzerino, G; Ortonne, JP; Puissant, A; Rocchi, S; Tartare-Deckert, S; Zamoum, T, 2009) |
| "The PPAR-gamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J(2) and ciglitazone, and the PPAR-alpha ligand, WY-14643, were examined for their effects on proliferation and apoptosis of A375 melanoma, DU145 and PC3 prostate cancer, and MB-MDA-231 breast cancer." | 3.73 | PPAR-gamma ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells. ( Liu, H; Meadows, GG; Núñez, NP, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Botton, T | 2 |
| Puissant, A | 2 |
| Bahadoran, P | 1 |
| Annicotte, JS | 1 |
| Fajas, L | 2 |
| Ortonne, JP | 2 |
| Gozzerino, G | 1 |
| Zamoum, T | 1 |
| Tartare-Deckert, S | 2 |
| Bertolotto, C | 2 |
| Ballotti, R | 2 |
| Rocchi, S | 2 |
| Schadendorf, D | 1 |
| Cheli, Y | 1 |
| Tomic, T | 1 |
| Giuliano, S | 1 |
| Deckert, M | 1 |
| Paulitschke, V | 1 |
| Gruber, S | 1 |
| Hofstätter, E | 1 |
| Haudek-Prinz, V | 1 |
| Klepeisz, P | 1 |
| Schicher, N | 1 |
| Jonak, C | 1 |
| Petzelbauer, P | 1 |
| Pehamberger, H | 1 |
| Gerner, C | 1 |
| Kunstfeld, R | 1 |
| Placha, W | 2 |
| Gil, D | 1 |
| Dembińska-Kieć, A | 1 |
| Laidler, P | 2 |
| Núñez, NP | 1 |
| Liu, H | 1 |
| Meadows, GG | 1 |
| Grabacka, M | 1 |
| Urbanska, K | 1 |
| Płonka, PM | 1 |
| Reiss, K | 1 |
7 other studies available for ciglitazone and Melanoma
| Article | Year |
|---|---|
In vitro and in vivo anti-melanoma effects of ciglitazone.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Re | 2009 |
Peroxisome proliferator-activating receptors: a new way to treat melanoma?
Topics: Antineoplastic Agents; Apoptosis; Humans; Melanoma; PPAR gamma; Signal Transduction; Skin Neoplasms; | 2009 |
Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Chemokine CXCL1; | 2011 |
Proteome analysis identified the PPARγ ligand 15d-PGJ2 as a novel drug inhibiting melanoma progression and interfering with tumor-stroma interaction.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromans; Hu | 2012 |
The effect of PPARgamma ligands on the proliferation and apoptosis of human melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Division; Cell Line, Tumor; DNA; Dose-Resp | 2003 |
PPAR-gamma ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells.
Topics: Amino Acids; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferatio | 2006 |
PPAR gamma regulates MITF and beta-catenin expression and promotes a differentiated phenotype in mouse melanoma S91.
Topics: Alitretinoin; Animals; Antigens, Differentiation; Antineoplastic Agents; beta Catenin; Blotting, Wes | 2008 |